LAUSR

A large body of evidence suggests a mechanistic link between oxidized lipids and atherosclerosis. Oxysterols and 4-hydroxynonenal (HNE), the major products deriving from LDL oxidation, are consistently present in inflamed and atherosclerotic arteries and they play a key role in the development of atherosclerosis (1,2). Due to the fact that atherosclerosis is a leading cause of mortality in Western countries, it is of increasing importance to understand the various molecular mechanisms induced by oxysterols and HNE, as well as to identify new markers to distinguish between stable and unstable atherosclerotic plaques. Since chronic inflammation and matrix degradation might play a key role in plaque instability, we investigated the effect of oxysterols and HNE on various inflammatory molecules and MMP-9 expression in promonocytic U937 cells. In U937 cells, both oxysterols and HNE induced the expression of several cytokines and MMP-9 through TLR4 activation. These oxidized lipids also sustained inflammation by upregulating COX-2 and mPGES-1 levels, enzymes that cooperate to catalyze the conversion of arachidonic acid to PGE2. Inhibition of inflammatory molecule formation decrease MMP-9 release by macrophages, underlying the crucial role of inflammatory response in MMP-9 overexpression, a major marker of atherosclerotic plaque instability. Recently, it has been reported that proprotein convertase PCSK6, a new marker of plaque instability, is overexpressed in symptomatic carotid plaques. In connection with this, we are now investigating whether an oxysterol mixture and HNE can modulate the expression of PCSK6. Preliminary results indicate that both oxysterols and HNE upregulate PCSK6 in U937 cells. The downregulation of PCSK6 by siRNA significantly reduced MMP-9 activity induced by oxidized lipids, underlying a possible link between PCSK6 activity and MMP activation. Our results suggest that oxysterols and HNE contribute to atherosclerotic plaque instability by enhancing the inflammatory response and favouring matrix degradation through MMP-9 upregulation. Moreover, preliminary results indicate that PCSK6, upregulated by oxysterols or HNE, might play a key role in plaque instability by increasing MMP activity. These results might provide strong incentive for the development of new therapeutic strategies to counteract the risk of atherosclerotic plaque rupture and thrombosis, which cause acute coronary syndromes.